An update on butterbur (Petadolex) – we still don’t recommend it

August 17, 2013

The manufacturer of Petadolex brand of butterbur sent me an email saying that the FDA conducted an inspection of their manufacturing plant in Germany. However, my concerns about butterbur, which I mentioned in a previous blog post, has not been addressed. Here is my email response to the manufacturer:
“Thank you for this additional information. It is good to see that the FDA conducted a “comprehensive inspection” of the manufacturing facility in Germany. However, my concerns about the safety of Petadolex are not due to possible deficiencies in manufacturing, but are related to the extraction process. As far as I know, this is why German and UK governments still do not allow the sale of Petadolex and this is why I do not recommend Petadolex to my patients. I am also concerned that because Petadolex is fairly expensive, many patients will decide to buy a cheaper brand of butterbur, which can be truly dangerous. Once Petadolex is cleared for sale in Germany I will be happy to resume recommending it to my migraine patients”.

Written by
Alexander Mauskop, MD
Continue reading
August 2, 2026
Alternative Therapies
A Wearable Device May ImproveBalance in Aging Adults and Possibly Vestibular Migraine
This technology uses imperceptible electrical stimulation delivered through electrodes placed behind the ears and on the upper neck. Early studies and pilot trials suggest improvements in balance and gait, with a favorable safety profile, but larger sham-controlled studies that measure actual falls, not just test performance, are still needed.
Read article
July 18, 2026
Alternative Therapies
Why Everyone Should Have Their Vitamin D Level Checked, And Why 'Normal' Isn't Good Enough
Vitamin D deficiency is common, often missed, and easy to correct. In this post I explain why “normal” lab values can be misleading, how vitamin D affects headaches, heart and brain health, and what levels and doses I recommend for my patients.
Read article
July 13, 2026
Brain disorders
fMRI-guidedTMS targeting improves outcomes
This post reviews new data showing that fMRI‑guided, connectivity‑based TMS targeting improves response rates in treatment‑resistant depression and likely other conditions. By mapping each patient’s brain circuits, clinicians can move beyond a one‑size‑fits‑all DLPFC target to condition‑specific and patient‑specific sites, a particularly important advance for migraine and network‑based pain disorders.
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe